REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Effervescent Or Pressurized Fluid Containing > Organic Pressurized Fluid Organic Pressurized FluidOrganic Pressurized Fluid patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.08/16/07 - 20070189978 - Compositions and methods for dermally treating musculoskeletal pain The present invention is drawn to solidifying formulations for dermal delivery of a drug for treating musculoskeletal pain, inflammation, joint pain, etc. The formulation can include a drug selected from certain drug classes, a solvent vehicle, and a solidifying agent. The solvent vehicle can include a volatile solvent system having ... 08/16/07 - 20070189977 - Spray-on formulations and methods for dermal delivery of drugs The present invention is drawn to sprayable formulations, methods of drug delivery, and resultant solidified layers for dermal delivery of a drug. The formulation can include a drug, a non-volatile solvent system, a solidifying agent, and a propellant. The formulation can have an initial viscosity suitable to be expelled out ... 08/16/07 - 20070189976 - Administering pharmaceutical compositions to the mammalian central nervous system Methods, compositions and systems are provided for the non-invasive transnasal and transocular drug delivery to the central nervous system using eriodictyon fluid extract technology. By administration through the olfactory nerve or the optical nerve, the delivery of a biologically active substance of interest into the CNS and CSF can be ... 08/02/07 - 20070178050 - Methods and systems for the delivery of corticosteroids having an increased lung depositon The present invention relates to methods and systems for the delivery of a corticosteroid comprising (1) an inhalable aqueous mixture comprising a corticosteroid and a solubility enhancer and (2) an inhalable nebulizer, wherein the delivery of the aqueous mixture comprising the corticosteroid by the nebulizer results in an enhanced pharmacokinetic ... 08/02/07 - 20070178049 - Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile The present invention relates to methods and systems for the delivery of a corticosteroid comprising (1) an inhalable aqueous mixture comprising a corticosteroid and a solubility enhancer and (2) an inhalable nebulizer, wherein the delivery of the aqueous mixture comprising the corticosteroid by the nebulizer results in an enhanced pharmacokinetic ... 08/02/07 - 20070178048 - Antiviral composition comprising p-menthane-3,8-diol The use of p-menthane-3,8-diol (PMD) as an antiviral agent. ... 07/19/07 - 20070166237 - Method for the treatment of bone disorders Disclosed are methods for treating bone disorders in mammals. The methods comprise a loading period with a bisphosphonate followed by a maintenance period. The loading dose is two to twenty times per day greater than the corresponding maintenance dose. Also disclosed are compositions and kits for implementing the methods disclosed ... 07/12/07 - 20070160542 - Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile The present invention relates to methods and systems for the delivery of a corticosteroid comprising (1) an inhalable aqueous mixture comprising a corticosteroid and a solubility enhancer and (2) an inhalable nebulizer, wherein the delivery of the aqueous mixture comprising the corticosteroid by the nebulizer results in an enhanced pharmacokinetic ... 07/05/07 - 20070154403 - Oral, pulmonary and transmucosal delivery composition Provided, among other things, is a delivery composition comprising: an aqueous carrier; a lipid component suspended in the carrier comprising significant amounts of type A lipid, fatty acid, and bilayer-stabilizing steroid(s), wherein type A lipid is one or more of any of phospholipid, ceramide(s) sphingomyelin(s) and glucocerebroside(s); and a bioactive ... 07/05/07 - 20070154402 - Topical pharmaceutical foam composition A stable topical alcohol-free aerosol foam containing one or more keratolytic agents is provided. The foam-forming formulation is an emulsion which contains an HFA propellant and one or more keratolytic agents. The emulsion has an oil phase and an aqueous, i.e. water-containing, phase. The active agent(s) may be present in ... 07/05/07 - 20070154401 - Compositions and methods for enhanced mucosal delivery of parathyroid hormone Pharmaceutical compositions and methods are described comprising at least a parathyroid hormone peptide (PTH) preferably PTH1-34 and one or more mucosal delivery-enhancing agents for enhanced nasal mucosal delivery of PTH, for treating or preventing osteoporosis or osteopenia in a mammalian subject, preferably a human. ... 07/05/07 - 20070154400 - Compositions and methods for enhanced mucosal delivery of parathyroid hormone Pharmaceutical compositions and methods are described comprising at least a parathyroid hormone peptide (PTH) preferably PTH1-34 and one or more mucosal delivery-enhancing agents for enhanced nasal mucosal delivery of PTH, for treating or preventing osteoporosis or osteopenia in a mammalian subject, preferably a human. ... 06/21/07 - 20070140979 - Method for accelerating the rate of mucociliary clearance The instant invention provides for a composition and method for using Kunitz-type serine protease inhibitors, e.g., aprotinin or bikunin, for stimulating the rate of mucociliary clearance of mucus and sputum in lung airways of subjects afflicted with mucociliary dysfunctions such as cystic fibrosis. ... 06/21/07 - 20070140978 - Adrenergic complement inhaler Pharmaceutical compositions consisting essentially of: (a) an adrenergic complement; and (b) a pharmaceutically-acceptable carrier suitable for respiratory administration. Adrenergic complements include ascorbates, tocopherols, and polycarboxylic acid chelators. Methods are also provided for the treatment of respiratory disorders, particularly asthma. ... 06/21/07 - 20070140976 - Aqueous inhalation pharmaceutical composition An aqueous inhalation pharmaceutical composition comprising a polypeptide or protein is provided. The composition of the present invention can improve the bioavailability of the polypeptide and protein, and avoid inducing toxicity in the lung. ... 06/14/07 - 20070134166 - Airway alkalinization as therapy for airway diseases The present invention relates to a method of treating asthma by raising the pH of the airways of an individual. The effect can be mediated directly by administering a pharmaceutically acceptable basic solution or alternatively, the effect can be mediated by enhancing the activity of glutaminase. ... 06/14/07 - 20070134165 - Use of ciclesonide for the treatment of respiratory disease in a smoking patient The invention relates to a new method of treatment of respiratory diseases, in particular the treatment of asthmatic smoking patients. The method comprises the administration of a pharmaceutical composition comprising ciclesonide. ... 06/07/07 - 20070128123 - Tiotropium containing hfc solution formulations This invention relates to tiotropium containing stable pharmaceutical solution formulations suitable for aerosol administration. More particularly, this invention relates to tiotropium containing stable pharmaceutical solution formulations suitable for aerosol administration wherein either an inorganic acid or an organic acid is added to the aerosol solution formulation which contains a tiotropium ... 06/07/07 - 20070128122 - Volatile material-containing compositions having an end of service indicator Volatile material-containing compositions having an end of service indicator and methods of indicating the end of service of a volatile material emitted from a volatile material-containing composition are disclosed. ... 05/31/07 - 20070122352 - Inhalation drug combinations A method for treating respiratory disorders by administrating by inhalation an effective amount of a β2-receptor agonist, an acceptable amount of a corticosteroid, and HFA 134a, to a patient in need thereof, is disclosed. Preferably, the β2-receptor agonist is salmeterol or a physiologically acceptable salt thereof, and the corticosteroid is ... 05/31/07 - 20070122351 - Inhalation drug combinations A method for treating respiratory disorders by administrating by inhalation an effective amount of a β2-receptor agonist, an acceptable amount of a corticosteriod, and HFA 134a, to a patient in need thereof, is disclosed. Preferably, the β2-receptor agonist is salmeterol or a physiologically acceptable salt thereof, and the corticosteriod is ... 05/31/07 - 20070122350 - Safe and effective methods of administering therapeutic agents In one embodiment, the invention relates to a kit for administering a lipid-based platinum compound formulation via inhalation comprising: an inhalation device comprising a lipid-based platinum compound formulation, a demistifier tent of sufficient size to at least cover a patient's head and the inhalation device, and instructions for use thereof. ... 05/31/07 - 20070122349 - Measuring particle size distribution in pharmaceutical aerosols Disclosed herein are methods for measuring the particle size distribution of a pharmaceutical aerosol, including methods utilizing laser diffraction. ... 05/24/07 - 20070116649 - Antibiotic formulations, unit doses, kits, and methods An aqueous or powder composition includes anti-gram-negative antibiotic or salt thereof being present at an amount ranging from about 100 mg/ml to about 200 mg/ml. Another aqueous or powder composition includes anti-gram-positive antibiotic or salt thereof being present at a concentration ranging from about 0.6 to about 0.9 of the ... 05/17/07 - 20070110677 - Delivery of drugs to mucosal surfaces Liquid pharmaceutical compositions for administration to a mucosal surface, including fentanyl and a pectin with a low degree of esterification are described. Such compositions gel, or can be adapted to gel, at the site of application in the absence of an extraneous source of divalent metal ions. ... 05/17/07 - 20070110676 - Compositions useful for prevention and treatment of common cold and influenza-like symptoms The present invention is directed to compositions that are useful in the prevention and treatment of common cold and influenza-like symptoms due to respiratory tract viral infections. These compositions comprise a guaiacol component, and a mucoadhesive polymer wherein the pH of the composition is about 5.5 or less. ... 05/10/07 - 20070104653 - Use of inhaled gaseous nitric oxide as a mucolytic agent or expectorant Methods and devices for treating excess mucus accumulation in mammals by administering gaseous inhaled nitric oxide or nitric oxide releasing compounds as a mucolytic agent or expectorant are provided. Delivery of gaseous nitric oxide can be made nasally or orally and is preferably substantially coincident with inhalation of the mammal ... 05/10/07 - 20070104652 - Pharmaceutical spray formulation comprising a hydro fluor alkane and an acylated cyclodextrin Novel Formulations Partially and fully acylated cyclodextrins have been found to be soluble in HFA propellants, and therefore can be used to formulate stable HFA pMDIs both as suspensions and solutions. ... 05/10/07 - 20070104651 - Therapeutic foam A therapeutic foam for the treatment of, inter alia, varicose veins comprises a sclerosing solution foamed with a physiological gas such as carbon dioxide, oxygen or a mixture thereof. The foam has a nitrogen content of less than 0.8%. It may be generated using a pressurised canister system incorporating a ... 05/03/07 - 20070098646 - Aerosol propellants comprising unsaturated fluorocarbons Disclosed herein are propellants comprising fluorocarbons and/or hydrofluorocarbons. Also disclosed are sprayable compositions comprising the propellants. ... 05/03/07 - 20070098645 - Intranasal delivery of compounds that reduce intrancranial pressure Increasing intranasal lymphatic circulation as a means of decreasing intracranial pressure in traumatic brain injury. ... 05/03/07 - 20070098644 - Delivery of a combination therapy for asthma and chronic obstructive pulmonary disease A method of delivery of a combination therapy to the pulmonary system that includes providing a nebulizer and a fluid comprising a long-acting corticosteroid, a long-acting beta-agonist, and a long-acting anticholinergic in a pharmaceutically acceptable vehicle, and administering the solution to the patient using the nebulizer. The corticosteroid is budesonide, ... 04/19/07 - 20070086954 - Method and apparatus for treatment of respiratory infections by nitric oxide inhalation Methods for suppressing, killing, and inhibiting pathogenic cells, such as microorganisms associated with a respiratory infection within the respiratory tract of an animal are described. Methods include the step of exposing the pathogenic cells to an effective amount of nitric oxide, such as through inhalation of nitric oxide gas, in ... 04/19/07 - 20070086953 - Medicinal aerosol formulation products with improved chemical stability The present invention relates to a medicinal aerosol formulation product with improved chemical stability. The product is a pressurized metered dose inhaler including an aerosol canister equipped with a metering valve provided with sealing rings and/or gaskets made of a vulcanisate of an elastomeric composition of a butyl rubber, a ... 04/19/07 - 20070086952 - Rapid acting and prolonged acting inhalable insulin preparations It has been discovered that by combining a chelator, such as ethylenediaminetetraacetic acid, with an acidifier, such as citric acid, the insulin is absorbed much more rapidly than in the absence of the chelator and acidifier, with a commercially available rapid, intermediate or long lasting insulin such as glargine, one ... 04/12/07 - 20070081947 - Solid active ingredient formulation The present invention relates to novel solid active substance formulations comprising solid active substances, dispersants, and polymers which together result in a fine-particle, predominantly amorphous mixture, to a process for the preparation thereof and to the use thereof for application of the contained bioactive active substances. ... 04/05/07 - 20070077209 - Stabilized particle dispersions containing nanoparticles In one aspect, the invention provides a stable dispersion comprising a continuous phase comprising a continuous liquid phase and a plurality of organic nanoparticles; and a dispersed phase comprising particles dispersed in the continuous phase. ... 04/05/07 - 20070077208 - Pharmaceutical foam The present invention provides various pharmaceutically active topical delivery compositions. In particular, compositions of the present invention are present in a pressurized contained comprising a quick-breaking alcoholic foaming agent, such that when the composition is released, i.e., dispensed, from the pressurized container, a quick-breaking temperature sensitive foam is formed. In ... 03/29/07 - 20070071688 - Pharmaceutical compositions for transdermal administration of anti-inflammatory agents A pharmaceutical composition for transdermal administration comprising a polymeric release matrix capable of forming a supple film after drying, selected among cellulose polymers or copolymers; an active principle selected among the group of non-steroid anti-inflammatory agents comprising at least one carboxylic or metal carboxylate group; a transcutaneous absorption promoter; water; ... 03/29/07 - 20070071687 - Intranasal benzodiazepine compositions A pharmaceutical composition for intranasal administration to a mammal. The pharmaceutical composition comprises an effective amount of a benzodiazepine or pharmaceutically acceptable salt thereof; and a nasal carrier. In some embodiments, the pharmaceutical composition when administered intranasally produces a rapid physiological response. Pharmaceutical compositions may also include at least one ... 03/29/07 - 20070071686 - Liquid preparation containing tobramycin The application describes a sterile aqueous inhalation solution containing the active agent tobramycin. The preparation has a high content of active agent (about 80 to 120 mg/ml of tobramycin) and contains an acidic adjuvant, but contains only a low concentration of sodium chloride (at most about 2 mg/ml). It can ... 03/22/07 - 20070065370 - Suspension aerosol formulationis of pharmaceutical products Pharmaceutical preparations for producing powder aerosols using propellant gases which use TG 227, and possibly also TG 11, TG 12, TGH 114, propane, butane, pentane or DME. ... 03/22/07 - 20070065369 - Novel methods and composition for delivering macromolecules to or via the respiratory tract A composition comprises a lipid-based microstructure with at least one bioactive macromolecule. The composition provides improved bioavailability and is capable of rapidly releasing a bioactive macromolecule. It is believed that the improved bioavailability is due, at least in part, to the reduction of scavenging by bronchoalveolar macrophages and/or mucociliary clearance. ... 03/22/07 - 20070065368 - Compositions and methods for suppressing fibrocytes and for detecting fibrocyte differentiation The present invention relates to the ability of SAP to suppress fibrocytes. It also relates to the ability of IL-12, laminin-1, cross-linked IgG and IgG aggregates to suppress fibrocytes. Methods and compositions for suppressing fibrocytes using these proteins are provided. These methods are useful in a variety of applications including ... 03/22/07 - 20070065367 - Method of treating pulmonary disease with interferons A method of treating a pulmonary disease such as, for instance idiophathic pulmonary fibrosis (IPF) and asthma, comprising administering an aerosolized interferon such as interferon α, interferon β or interferon γ in a therapeutically effective amount is provided herein. Also, pharmaceutical compositions of one or more aerosolized interferon(s) are provided. ... 03/15/07 - 20070059251 - Method of attenuating bruise formation The present invention provides a method of attenuating the formation or reducing the severity of a bruise in the tissue of a patient via applying a composition comprising a hydrophilic foam substrate and a polymeric hydrophilic agent to a portion of the surface of the skin in an amount and ... 03/15/07 - 20070059250 - Sprayable personal lubricant This invention relates to personal lubricant compositions that are capable of being sprayed to a targeted area while maintaining lubricity. ... 03/15/07 - 20070059249 - Acute treatment of social phobia Methods and compositions for the treatment of social phobia are provided, including administering a therapeutically effective amount of an androsta-4,16-dien-3-ol steroid to an individual in need of treatment and a pharmaceutical composition for the treatment of social phobia having a therapeutically effective amount of an androsta-4,16-dien-3-ol steroid. Therapeutically effective amounts ... 03/08/07 - 20070053841 - Use of 1,1,1,2-tetrafluoroethane for measuring lung function, especially for determining the functional residual capacity (frc) of the lungs 1,1,1,2-Tetrafluoroethane (norflurane) is used as a tracer/trace gas for measuring the lung function because of its simple detectability, physiological harmlessness, environmental friendliness and ready availability. Especially advantageous is the possibility of the optical concentration measurement of 1,1,1,2-tetrafluoroethane for the measurement of the lung function and especially for the determination of ... 03/01/07 - 20070048229 - Buccal, polar and non-polar spray containing atropine Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide atropine for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, atropine, and optional taste mask and/or flavoring ... 02/22/07 - 20070041911 - Hfc solution formulations containing salbutamol hydrochloride or salbutamol citrate This invention relates to stabilized aerosol solution formulations containing acid addition salts of salbutamol, which are suitable for administration by metered dose inhalers (MDIs). More particularly, this invention relates to solution formulations containing one of the aforementioned salts of salbutamol, preferably salbutamol hydrochloride or salbutamol citrate, more preferably one of ... 02/22/07 - 20070041910 - Pharmaceutical spray compositions comprising a bioactive agent, at least one volatile silicone and a non-volatile oily phase Sprayable pharmaceutical compositions suited for improved transdermal penetration contain a) at least one bioactive agent, notably at least one derivative of vitamin D, (b) at least one volatile silicone and c) a non-volatile oily phase, formulated into d) a pharmaceutically acceptable vehicle therefor. ... 02/08/07 - 20070031346 - Generation of therapeutic microfoam A method for producing a microfoam suitable for use in scleropathy of blood vessels comprises introducing a physiologically acceptable blood-dispersible gas into a container (1) holding an aqueous sclerosant liquid and releasing the mixture of blood-dispersible gas and sclerosant liquid, whereby upon release of the mixture the components of the ... 02/08/07 - 20070031345 - Generation of therapeutic microfoam A method for producing a microfoam suitable for use in scleropathy of blood vessels comprises introducing a physiologically acceptable blood-dispersible gas into a container (I) holding an aqueous sclerosant liquid and releasing the mixture of blood-dispersible gas and sclerosant liquid, whereby upon release of the mixture the components of the ... 02/08/07 - 20070031344 - Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis Pharmaceutical compositions are described that contain one agent for treatment of sinusitis and a surfactant. The compositions are prepared to have a surface tension that renders the composition effective for treatment of sinusitis. ... 02/08/07 - 20070031343 - Flavored medicinal inhalant A flavored medicinal inhalant includes a medicant, a carrier and an effective amount of a flavoring agent. Carriers such as saline or bacteriostatic water may be utilized. Flavoring agents include natural and artificial flavors chosen from synthetic flavor oils and flavoring aromatics, and/or oils, oleo resins and extracts derived from ... 02/08/07 - 20070031342 - Sustained release microparticles for pulmonary delivery A composition of microparticles for delivery to the pulmonary system provides sustained release of a pharmaceutical agent. The microparticles comprise a lipid structural matrix comprising a multilamellar structure of lipid bilayers having lipid chains ordered in an LβL phase. The lipid matrix at least partially encapsulates the pharmaceutical agent at ... 02/08/07 - 20070031341 - Methods of delivering therapeutics to the brain Intranasal iontophoretic administration of therapeutics such as Reduced Water (RW) or lubeluzole as a means of treating diseases of the CNS involving oxidative stress. ... 02/08/07 - 20070031340 - Thin-film drug delivery article and method of use An article for use in an aerosol device, for producing an aerosol of a drug composition is disclosed. The article includes a heat-conductive substrate having a surface with a selected surface area, and a drug composition film on the substrate surface having a selected film thickness of between 0.05 and ... 02/01/07 - 20070025922 - Method of attenuating neurogenic pain The present invention provides a method of attenuating the formation or reducing the severity of neurogenic pain in the tissue of a patient via applying a composition comprising a hydrophilic foam substrate and a polymeric hydrophilic agent to a portion of the surface of the skin in an amount and ... 02/01/07 - 20070025921 - Inhibition of olfactory neurosensory function to treat eating disorders and obesity The use of calcium channel blockers administered intra-nasally to inhibit olfactory sensory perception to treat eating disorders, including obesity, is described. Also described is a method of reducing food intake in a subject by administering a pharmaceutical composition comprising an effective amount of a calcium channel blocker to the nasal ... 02/01/07 - 20070025920 - Stable pharmaceutical solution formulations for pressurized metered dose inhalers Aerosol solution formulations for use in an aerosol inhaler include 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methyl ethyl]amino]ethyl]-2(1H)-quinolinone or a salt thereof, preferably the hydrochloride thereof, as an active ingredient, a propellant containing a hydrofluoroalkane, and a cosolvent, stabilized by addition of a specific small amount of a high concentrated phosphoric acid and optionally by the ... 02/01/07 - 20070025919 - Systems and methods for delivery of a therapeutic agent Methods and apparatus are provided for applying an fragment of a neurotoxin such as the active light chain (LC) of the botulinum toxin (BoNT), such as one of the serotype A, B, C, D, E, F or G botulinum toxins, via permeabilization of targeted cell membranes to enable translocation of ... 01/25/07 - 20070020196 - Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension An inhalable unit dose liquid formulation containing SAE-CD and corticosteroid is provided. The formulation is adapted for administration to a subject by nebulization with any known nebulizer. The formulation can be included in a kit. The formulation is administered as an aqueous solution or concentrated composition. The formulation is employed ... 01/25/07 - 20070020195 - Nasally administered appetite suppressants Methods are described for suppressing appetite through the intranasal administration of a sodium channel blocker. It has long been known that smell and taste are an important part of how the body prepares for a meal, for example the cephalic phase of insulin release before a meal. Depressing the sense ... 01/25/07 - 20070020194 - Nasally administered appetite suppressant Methods are described for suppressing appetite through the intranasal administration of a sodium channel blocker. It has long been known that smell and taste are an important part of how the body prepares for a meal, for example the cephalic phase of insulin release before a meal. Depressing the sense ... 01/25/07 - 20070020193 - Dronabinol compositions and methods for using same In various embodiments, the present invention provides pharmaceutical compositions comprising delta-9-THC and to methods of administering such compositions to a patient in need of delta-9-THC therapy. ... 01/25/07 - 20070020192 - Receptor specific transepithelial transport of therapeutics The present invention relates in general to methods and products for initiating an immune response against an antigen, and in particular relates to transepithelial delivery of antigens to provoke tolerance and immunity. The present invention further relates to methods and products for the transepithelial delivery of therapeutics. In particular, the ... 01/25/07 - 20070020191 - Potentiation of glucose elimination Methods related to the treatment of diabetes and improving the efficiency of insulin utilization are provided. The method enables effective control of prandial glucose levels while reducing the risk of postprandial hypoglycemia. In particular, methods of potentiating the activity of endogenous insulin in type 2 diabetics and exogenous long-acting insulin ... 01/25/07 - 20070020190 - Medicament comprising a highly potent long-lasting beta2-agonist in combination with other active ingredients The present invention relates to the use of a bronchodilator in combination with one or more further active ingredients for the treatment of respiratory disorders and especially asthma and chronic obstructive pulmonary disease (COPD), and to pharmaceutical compositions containing said active ingredients. In particular, the invention relates to the use ... 01/18/07 - 20070014736 - Methods of delivering corticotroph-derived glycoprotein hormone Methods for treating diseases comprising delivering CGH by aerosol delivery and comprising administering a lesser amount of CGH than TSH are described. ... 01/18/07 - 20070014735 - Buccal delivery system A delivery formulation and system for delivering inactivated bioactive peptides to the body. The formulation includes effective amounts of the peptide as well as a mucosal permeation enhancer selected from the group consisting of quaternary ammonium salts. The system can be used by spraying the formulation into the buccal cavity, ... 01/18/07 - 20070014734 - Glucuronidated nebivolol metabolites This invention provides glucuronidated nebivolol metabolites and pharmaceutical compositions of glucuronidated nebivolol metabolites for treatment of cardiovascular diseases. In addition, this invention also provides compositions comprising nebivolol and/or at least one glucuronidated metabolite of nebivolol and/or at least one other active compound in a pharmaceutically acceptable carrier. This invention also ... 01/18/07 - 20070014733 - Hydroxylated nebivolol metabolites Hydroxylated nebivolol metabolites increase NO release from human endothelial cell preparations in a concentration dependent fashion following acute administration. In addition, hydroxylated nebivolol metabolites, including but not limited to 4-hydroxy-6,6′difluoro-, 4-hydroxy-5-phenol-6,6′difluoro-, and 4-hydroxy-8-pheno-6,6′difluoro-, have the ability to increase the capacity for NO release in human endothelial cells following chronic administration. ... 01/11/07 - 20070009443 - Method for inhibiting occupation by rhinovirus of cell in the nasal membrane A composition and method for modifying the composition of a cell in a nasal epithelial membrane to improve the ability of the cell to defend against rhinovirus. ... 01/04/07 - 20070003486 - Ointment wound spray A spray-on topical wound debrider spray is prepared forming a mist, spray or foam which will not drip significantly after application. The preferred wound debrider is papain. The spray contains a surfactant emulsifier admixture having a composition viscosity of from about 5000 cps to about 50,000 cps and is preferably ... 12/28/06 - 20060292080 - Vitamin formulation A pharmaceutical aerosol foam composition, comprising: an effective amount of a pharmaceutically active ingredient, wherein said pharmaceutically active ingredient is a vitamin or analogue thereof; an occlusive agent; an aqueous solvent; an organic cosolvent; wherein the pharmaceutically active ingredient is insoluble in both water and the occlusive agent; and the ... 12/21/06 - 20060286039 - Novel treatment for pathological aggression The use of compounds belonging to the class of substituted pentanedioic acids to control aggressive behavior provides new means of treatment for this syndrome. ... 12/21/06 - 20060286038 - Pulmonary surfactant formulations Synthetic pulmonary surfactant compositions comprising dipalmitoyl phosphatidylcholine, phosphatidylglycerol, and essentially neutral lipid, and having essentially no 1-palmitoyl 2-oleoyl phosphatidylglycerol and essentially no palmitic acid are provided. Methods for treating respiratory disease are also provided comprising administering a therapeutically effective amount of a synthetic pulmonary surfactant comprising dipalmitoyl phosphatidylcholine, phosphatidylglycerol, and ... 12/14/06 - 20060280690 - Methods of preparing a foam comprising a sclerosing agent Present application discloses a device for generating and dispensing a foam for therapeutic use comprising a) a housing, b) a first chamber with gas at a substantially atmospheric pressure, a second chamber with at least one sclerosant agent c) an outlet for dispensing gas and the solution in the form ... 12/07/06 - 20060275218 - Foamable vehicle and pharmaceutical compositions thereof A hygroscopic pharmaceutical composition includes at least one hygroscopic substance at a concentration sufficient to provide an Aw value of at least 0.9 and an antiinfective agent. A foamble pharmaceutical carrier includes about 50% to about 98% of a polar solvent selected from the group consisting of a polyol and ... 11/30/06 - 20060269485 - Antibiotic kit and composition and uses thereof The present invention relates to a therapeutic kit to provide a safe and effective dosage of an antibiotic agent, including an aerosol packaging assembly including: a container accommodating a pressurized product; and an outlet capable of releasing the pressurized product as a foam, wherein the pressurized product comprises a foamable ... 11/30/06 - 20060269484 - Medicament formulations Disclosed are medicinal compositions, and devices, methods and systems which use same, comprising a propellant and at lease one medicinally active compound, said propellant comprising at least one fluoroolefin having at least two but less than seven carbon atoms. ... 11/23/06 - 20060263304 - Method of controlling alcohol intake and reversing alcohol effects A method for controlling or reversing the alcohol intake in the non-alcohol dependent individual both before or during their alcohol imbibing. This is accomplished by self-administering a spray directed into sensitive mucosal vein endings of the individual. There are at least three technologies to accomplish the above noted task. The ... 11/16/06 - 20060257325 - Method and package for storing a pressurized container containing a drug A method and package for storing a pressurized container which is filled with a drug formulation at a predetermined pressure. The drug formulation includes a mixture of a drug and a propellant. The package which encloses the pressurized container substantially prevents ingression of water vapor and particulate matter into the ... 11/16/06 - 20060257324 - Pharmaceutical solution formulations for pressurised metered dose inhalers A method for delivering two or more active drug substances to the lungs by inhalation from a single pressurized metered dose inhaler product, said inhaler containing a HFA/cosolvent based solution formulation wherein all the active drug substances are fully dissolved in the formulation. ... 11/02/06 - 20060246008 - Process for the formulation of therapeutic protein Therapeutic protein is formulated in a container made of flexible film, at least the interior surface of said container being fluoropolymer, which is preferably terminally sterilized in a sealed overwrap so as to be available for the formulating step in sterilized condition. ... 11/02/06 - 20060246007 - Use of osmolytes obtained from extremophilic bacteria the production of inhalable medicaments for the prophylaxis and treatment of pulmonary and cardiovascular diseases and an inhalation device comprising an osmolyte as active agent component The invention relates to the use of osmolytes, for example, ectoine, hydroxyectoine, firoin, firoin-A, diglycerol phosphate, cyclic diphosphoglycerate, 1,3-dimannosyl-di-myo-inositol-phosphate (DMIP) and/or diinositol phosphate and their equally effective derivatives and/or pharmacologically acceptable salts thereof, for the combating of pulmonary diseases caused by the effect of airborne particles and/or causally related cardiovascular ... 10/26/06 - 20060239930 - Process for nebulizing aqueous compositions containing highly concentrated insulin A process for nebulizing highly concentrated solutions of insulin for administration by inhalation. ... 10/26/06 - 20060239929 - Use of a clobetasol spray formulation to treat psoriasis The present invention provides a method for treating psoriasis, by spraying onto the skin with psoriasis daily for at least 4 weeks a pharmaceutical composition containing an effective amount of clobetasol propionate. A preferred pharmaceutical composition containing clobetasol propionate, ethyl alcohol, isopropyl myristate, and anionic surfactant. ... 10/26/06 - 20060239928 - Transmucosal administration of drug compositions for treating and preventing disorders in animals The invention includes compositions for transmucosal administration to an animal comprising at least one active agent and a pharmaceutically acceptable carrier. A preferred active agent is selected from the group consisting of meloxicam, carprofen, enrofloxacin, clemastine, diphenhydramine, digoxin, levothyroxine, cyclosporine, ondansetron, lysine, zolpidem, propofol, nitenpyram, ivermectin, milbemycin, and pharmaceutically acceptable ... 10/26/06 - 20060239927 - Drug for airway administration An agent for intra-airway administration comprising a compound having a PDE-IV inhibitory activity or the pharmaceutically acceptable salt thereof as an active ingredient which shows its concentration in lung tissues 350-times or more higher than its concentration in plasma when administered into the airway is provided. An agent for intra-airway ... 10/19/06 - 20060233714 - Use of a volatile liquid at atmospheric pressure and ambient temperature for the production of pharmaceutical or biological compositions A liquid which is a perfluorinated compound whose vapor pressure at 25° C. and atmospheric pressure is greater than or equal to 10,000 Pa (100 mbar) and whose boiling point is greater than or equal to 30° C. is used in the manufacture of a pharmaceutical and/or biological composition. The ... 10/12/06 - 20060228306 - Combination antihistamine and steroid medication The invention provides a topical pharmaceutical composition for application to the nasal or ocular mucosa which comprises (1) a pharmaceutical excipient suitable for topical administration, (2) an antihistamine drug and (3) a mast cell stabilizer, a non-steroidal anti-inflammatory drug, a phosphodiesterase inhibitor, an anti-IgE agent, heparin, a topical steroid or ... 10/12/06 - 20060228305 - Pharmaceutical compositions based on anticholinergics and inhibitors of tnf alpha synthesis or action The present invention relates to novel pharmaceutical compositions based on anticholinergics and TNF-alpha-antagonists, processes for preparing them and their use in the treatment of respiratory diseases. ... 10/05/06 - 20060222598 - Aerosol formulation for inhalation comprising an anticholinergic wherein X31 denotes an anion. ... 09/28/06 - 20060216242 - Suspending vehicles and pharmaceutical suspensions for drug dosage forms Suspending vehicles and pharmaceutical suspensions that include a biocompatible polymer that can be combined with a hydrophobic solvent and a hydrophilic solvent to provide vehicles and suspensions that are substantially free of stiff gels upon contact with an aqueous medium are provided. Vehicles and suspensions remain flowable out of a ... 09/21/06 - 20060210484 - Buccal, polar and non-polar spray containing testosterone Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide testosterone for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, testosterone or a pharmaceutically acceptable ester thereof, ... 09/21/06 - 20060210483 - Non-systemic antibiotic formulations and related method of use and treatment of upper respiratory infections A method of treatment and prevention of upper respiratory illnesses by airborne administration to a subject in need of such treatment a composition containing a therapeutically effective amount of a non-systemic antibiotic. ... 09/21/06 - 20060210482 - Chemical composition and method for cold and sinus relief A chemical composition and method for treatment of the common cold, sinusitis and other conditions associated with nasal congestion is provided. The chemical composition is made of predetermined concentrations of thymol, alcohol, eucalyptol, menthol, methyl salicylate, a preservative, saline solution and a buffer. The method includes the step of administering ... 09/21/06 - 20060210481 - Medicament dispenser A component of a medicament dispenser has a surface which, in use of the dispenser, contacts a medicinal formulation contained in the dispenser, said surface being presented by a fluorinated polymeric composition having CF3CHFCF3 as a monomer thereof. ... 09/14/06 - 20060204447 - Small particle liposome aerosols for delivery of anticancer drugs Provided herein is a method of treating primary lung cancer or metastatic cancer to the lung in an individual by delivering at least once to the respiratory tract of the individual via inhalation a nebulized liposomal aerosol comprising a dilauroylphosphatidylcholine liposome containing camptothecin or a derivative thereof in an amount ... 09/14/06 - 20060204446 - Topical immunotherapy and compositions for use therein The present invention is concerned with the use of at least one immunosuppressant, or a pharmaceutically acceptable salt, solvate of physiologically functional derivative thereof, in the treatment of topical immune disorders of the scalp, and scalp conditions, and compositions suitable for such use. ... 09/07/06 - 20060198790 - Buccal, polar and non-polar spray containing ondansetron Buccal aerosol sprays or capsules using polar and non-polar solvents have now been developed which provide ondansetron for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, ondansetron, and optional flavoring agent; formulation II: ... 08/31/06 - 20060193786 - Pharmaceutical composition for intranasal administration containing a cgrp antagonist The invention relates to pharmaceutical compositions for nasal application, comprising selected CGRP antagonists which are described in WO 98/11128, as well as a process for the preparation thereof. ... 08/31/06 - 20060193785 - Pharmaceutical aerosol formulations for pressurized metered dose inhalers comprising a sequestering agent Aerosol solution formulation for use in an aerosol inhaler which includes at least one active ingredient selected from 20-ketosteroids and quinolinone derivatives, a propellant containing a hydrofluoroalkane, a cosolvent, and a specific amount of a sequestering agent that stabilizes the formulation. By way of example, the stabilizing agent may be ... 08/31/06 - 20060193784 - Scopolamine sublingual spray for the treatment of motion sickness This invention relates to a scopolamine spray for sublingual administration, used in the treatment and prevention of motion sickness, as well as the treatment and prevention of similar symptoms, such as nausea and vomiting, caused by conditions other than motion sickness. Also provided are methods of treatment, prevention and inhibition ... 08/31/06 - 20060193783 - Low dose corticosteroid composition The present invention relates to a low dose composition of budesonide suitable for administration of budesonide to mucosal membranes for the management of nasal symptoms associated with seasonal allergic rhinitis, perennial allergic rhinitis, perennial non-allergic rhinitis, nasal polyps, as well as prevention of post surgical polyps, chronic sinusitis and recurrent ... 08/24/06 - 20060188450 - System and method for suppressing a cough A system and method for suppressing coughs, congestion and related symptoms is provided. The composition sprayed into the oral cavity may contain a cough suppressant and other ingredients such as decongestants, flavorings, sweeteners, stablizers, and/or preservatives. The composition is sprayed into the oral cavity utilizing a spray pattern having a ... 08/24/06 - 20060188449 - Topical aerosol foams A stable topical aerosol foam is provided. The foam-forming formulation includes a HFA propellant and an active agent in an emulsion. The emulsion has an oil phase and an aqueous, i.e. water-containing, phase. The active agent may be present in either phase or dispersed in the emulsion. The oil phase ... 08/17/06 - 20060182690 - Alcoholic pump foam An alcoholic foam composition, which can be dispensed as a foam via a pump-foam system contains a) at least 52 to ≦99 wt % of an alcohol or mixture of alcohols, b) a surfactant or a surfactant mixture, c) at least one polyalkylene glycol, d) optionally, at least one foam ... 08/17/06 - 20060182689 - Process for separating out at least one organic compound Process for separating out at least one organic compound from a substrate containing the said organic compound, comprising a treatment of the substrate with an extraction medium comprising at least one fluoro compound with an atmospheric boiling point of greater than or equal to 25° C., so as to form ... 08/03/06 - 20060171898 - Corticosteroid-containing pharmaceutical composition The present invention provides a foamable pharmaceutical composition comprising a corticosteroid active substance, a quick-break foaming agent, a propellant and a buffering agent. The quick-break foaming agent typically comprises an aliphatic alcohol, water, a fatty alcohol and surface active agent. The compositions of the invention can be used to treat ... 08/03/06 - 20060171897 - Methods and formulations for the efficient delivery of drugs by nebulizer Formulations, methods and devices for producing formulations and methods for nebulizer delivery of formulations of water-insoluble drugs and drugs requiring storage in aqueous or other water-miscible pharmaceutically unacceptable vehicles for stability are provided. Also provided are methods for minimizing wastage of drugs administered by nebulizer, and for the achievement of ... 07/27/06 - 20060165604 - Buccal, polar and non-polar spray containing sumatriptan Buccal aerosol sprays or capsules using polar and non-polar solvents have now been developed which provide sumatriptan for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, sumatriptan, and optional flavoring agent; formulation II: ... 07/27/06 - 20060165603 - Solubilisation of drugs in hfa propellant by means of emulsions Emulsion and microemulsion aerosol formulations in a HFA propellant system include a medicament, one or more surfactant, optionally a cosolvent and water. Emulsion formulations are based on 0.1-% w/w surfactant and 1-10% w/w water. Microemulsion formulations are based on 1-20% w/w surfactant, 1-30% w/w cosolvent and 1-10% w/w water. Preferred ... 07/20/06 - 20060159627 - Method of preventing and treating airway remodeling and pulmonary inflammation using a2b adenosine receptor antagonists The present invention relates to methods of preventing airway remodeling using A2B adenosine receptor antagonists. This invention finds utility in the treatment and prevention of asthma, COPD, pulmonary fibrosis, emphysema, and other pulmonary diseases. The invention also relates to pharmaceutical compositions for use in the method. ... 07/20/06 - 20060159626 - Method for administering a cytokine to the central nervous system and the lymphatic system The present invention is directed to a method for delivering cytokines to the central nervous system and the lymphatic system by way of a tissue innervated by the trigeminal nerve and/or olfactory nerve. Cytokines include tumor necrosis factors, interleukins, interferons, particularly interferon-β and its muteins such as IFN-βser17. Such a ... 07/20/06 - 20060159625 - Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use Formulations are provided for pulmonary administration of an antifungal agent to a patient. Methods of using the formulations in the treatment of antifungal infections are also provided, including treatment of pulmonary aspergillosis with amphotericin B-containing formulations. Methods of manufacturing the formulations to achieve optimum properties are provided as well. ... 07/13/06 - 20060153777 - Aerosol formulation for inhalation containing an anticholinergic wherein X− is an anion; (b) a solvent comprising ethanol or mixtures of ethanol and water; (c) at least one pharmacologically acceptable acid. ... 07/06/06 - 20060147386 - System and method for intranasal administration of lorazepam A therapeutic composition of lorazepam and its pharmaceutically acceptable derivatives are provided for intranasal administration of at least one predetermined volumetric unit dose in the form of a spray by means that delivers one or more therapeutically prescribed unit doses that are highly accurate as to the volume discharged and ... 07/06/06 - 20060147385 - Nasal spray steroid formulation and method The present invention relates to an improvement in a method of contraception, in treatment of benign gynecological disorders, and in hormone replacement. The improved method includes administering intranasally an estrogenic compound and an androgenic compound, and in some embodiments an optional progestin compound, in a once-daily bolus formulation comprised of ... 07/06/06 - 20060147384 - Use of secretin-receptor ligands in treatment of cystic fibrosis (cf) and chronic obstructive pulmonary disease (copd) The invention is based on the finding that the secretin receptor is expressed in tissues present in the distal lung of humans. In patient with CF, levels of the receptor are elevated compared to normal tissue. Treatment of tissue by secretin stimulates the movement of negative ions in the tissue. ... 07/06/06 - 20060147383 - Sprayable compositions comprising pharmaceutical active agents, volatile silicones and a non-volatile oily phase Compositions in the form of a spray contain a pharmaceutical active agent, at least one volatile silicone and a non-volatile oily phase, formulated into a physiologically acceptable medium, are well suited for improved transdermal administration in cosmetics and dermatology. ... 07/06/06 - 20060147382 - Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases The invention relates to the administration of roflumilast and an anticholinergic agent selected from the group of an ipratropium, oxitropium or tiotropium salt for the treatment of respiratory diseases. ... 06/29/06 - 20060140873 - Aerosol pharmaceutical compositions A suspension aerosol composition suitable for use in pressurized metered dose inhalers has improved post-shaking suspension stability and comprises predetermined amounts of an active pharmaceutical ingredient (API) insoluble in the composition, a propellant comprising a hydrofluoroalkane (HFA), and a pharmaceutically acceptable non-aminated C1-6 organic acid. ... 06/29/06 - 20060140872 - Novel signaling pathway for the production of inglammatory pain and neuropathy This invention relates to a remedy for treating allergic contact dermatitis containing a substance having MEK inhibitory action as its effective component. ... 06/22/06 - 20060134006 - Chemical carrier based on a beta-limit dextrin A formulation, especially a pharmaceutical formulation, comprises an active agent and a carrier for the active agent, wherein the carrier comprises a beta-limit dextrin. The formulation may be a bioadhesive pharmaceutical formulation in which the beta-limit dextrin acts as a mucoadhesive agent. The active agent is a pharmaceutically active agent ... 06/15/06 - 20060127322 - Stable pharmaceutical budesonide preparation for producing propellant-free aerosols The invention relates to ethanol-containing pharmaceutical preparations for the production of propellant-free aerosols. ... 06/15/06 - 20060127321 - Pharmaceutical foam The present invention provides various pharmaceutically active topical delivery compositions. In particular, compositions of the present invention are present in a pressurized container comprising a quick-breaking alcoholic foaming agent, such that when the composition is released, i.e., dispensed, from the pressurized container, a quick-breaking temperature sensitive foam is formed. In ... 06/15/06 - 20060127320 - Method of delivering parathyroid hormone to a human What is described is a method of delivering PTH to a human, comprising exposing a layer of mucosal cells to a mixture of PTH and an enhancer, wherein the enhancer is capable of modulating the barrier function of a cellular tight junction. Specifically, the method of delivering PTH to a ... 06/15/06 - 20060127319 - Injectables in foam, new pharmaceutical applications The placing of a drug that is suitable for parenteral administration on bubbles formed with sterile gases produces an exponential increase in its active surface area with a decrease in the diameter of the bubble, modifies the kinetics of its distribution and, thanks to its micronisation, increases its therapeutic effect. ... 06/15/06 - 20060127318 - Composition and method of a topical treatment of neurodermatitis A composition for the topical treatment of dermal irritation and pain symptoms of neurodermatitis comprising a topical pharmaceutical formulation which contains a therapeutically appropriate dose of a sodium channel blocker selected from the group of ester- or amide-type local anesthetics, wherein the sodium channel blocker is released directly on or ... 06/15/06 - 20060127317 - Nasallly applicable pharmaceutical preparation and the production thereof The invention relates to a novel pharmaceutical preparation which can be administered nasally and is based on an aqueous solution, emulsion or the like which comprises at least one mucosally absorbable and/or locally acting active pharmaceutical ingredient, at least one preservative formed by benzalkonium chloride alone or together with other ... 06/08/06 - 20060120968 - Methods, systems and devices for delivery of pulmonary surfactants The invention is directed to methods, systems and devices for pulmonary delivery of aerosolized active agents in combination with positive pressure ventilation therapy and methods of treating respiratory dysfunction. ... 06/08/06 - 20060120967 - Solution forms of cyclodextrins for nasal or throat delivery of essential oils This invention further relates to a method for preventing or treating diseases or conditions of the oral cavity, throat or nose of warm-blooded animals including humans. More particularly, the invention pertains to a composition and method for spraying essential oils to the oral cavity, throat or nasal mucosa as cyclodextrin ... 06/08/06 - 20060120966 - Salmeterol superfine formulation The present invention relates to a pharmaceutical formulation for use in the administration of a long-acting β2-agonist by inhalation. In particular this invention relates to a chemically stable, highly efficient salmeterol HFA solution formulation to be administered by pressurised metered dose inhalers (pMDIs) characterized by a deep lung penetration. The ... 05/25/06 - 20060110331 - Compositions comprising azelastine and methods of use thereof The present invention provides pharmaceutical compositions comprising azelastine, or a pharmaceutically acceptable salt or ester thereof including azelastine hydrochloride, and optionally one or more additional active agents. Preferred such compositions further comprise one or more pharmaceutically acceptable carriers or excipients that reduce the amount of post-nasal drip, and/or that minimize ... 05/25/06 - 20060110330 - Inhalable pharmaceutical compositions containing an anticholinergic, formoterol, and a steroid wherein X− is an anion; a formoterol salt selected from formoterol fumarate and formoterol hemifumarate, or a hydrate, solvate, enantiomer, or mixtures of enantiomers thereof; and a steroid selected from ciclesonide, budesonide, and mometasone furoate, or a solvate or hydrate thereof. ... 05/25/06 - 20060110329 - Inhalable pharmaceutical compositions containing an anticholinergic, salmeterol, and a steroid wherein X− is an anion; salmeterol xinafoate, or a hydrate, solvate, enantiomer, or mixtures of enantiomers thereof; and a steroid selected from ciclesonide, budesonide, and mometasone furoate, or a solvate or hydrate thereof. ... 05/25/06 - 20060110328 - Method of delivering nasal spray A method of delivering a nasal spray. A sprayer having a formulation comprising olopatadine is provided. A spray of the formulation is delivered to a subject's nose. The spray may have a spray characteristic comprising a spray pattern having a longest axis of 20-45 mm, a shortest axis of 14-20 ... 05/18/06 - 20060104914 - Device and method for treatment of eyelid diseases A container has an impermeable outer membrane sized to fit generally within the peri-orbital region and sufficiently flexible to mold to the structure of the closed eye. Heat which is generated by an exothermic reaction inside the container, which provides steady-state heat to the eyelids. A soft, non-abrasive, lint-free material ... 05/18/06 - 20060104913 - Inhalable formulations for treating pulmonary hypertension and methods of using same The present invention is directed to an inhalable formulation for the treatment of pulmonary hypertension in a mammal (e.g., humans), wherein the formulation comprises at least one hypertension reducing agent, including but not limited to an angiotensin converting enzyme inhibitor, angiotensin receptor blocker, beta-blocker, calcium-channel blocker or vasodilator, or any ... 05/18/06 - 20060104912 - Mousse composition A pharmaceutical aerosol foam composition including an effective amount of a pharmaceutically active ingredient; an occlusive agent; an aqueous solvent; and an organic cosolvent, the pharmaceutically active ingredient being insoluble in both water and the occlusive agent; the occlusive agent being present in an amount sufficient to form an occlusive ... 05/18/06 - 20060104911 - Foamable alcohol The present invention is a foamable alcohol having at least one active ingredient. The active ingredient can be a prescription or non-prescription drug or medication. It either works on the skin or is absorbed transdermally and works on the body. Alcohol, such as ethyl alcohol is combined with a fluoro-surfactant, ... 05/11/06 - 20060099149 - Metered dose inhaler product The present invention relates to the provision and use of pressurised metered dose inhalers (MDIs) for the effective administration of pharmaceutical aerosol formulations. Such formulations comprise a drug, a propellant comprising one of either 1,1,1,2-tetrafluoroethane (HFA 134a) or 1,1,1,2,3,3,3-heptafluoropropane (HFA227) or a mixture thereof, a cosolvent having a higher polarity ... 04/27/06 - 20060088478 - Apparatus and method for applying cosmetic and/or therapeutic formulations An apparatus, a method for manufacturing the apparatus, and a method for dispensing a formulation to a person or animal using the apparatus, wherein the apparatus includes: a dispensing container; an amount of formulation contained in the container; and a propellant contained in the container, wherein the propellant comprises between ... 04/27/06 - 20060088477 - Compositions and methods of dispensing palliative or therapeutic agents The present invention is a palliative or therapeutic foam for medicating or treating affected biological tissue having a pH of 7.0 to 8.0 and including a hydrated dialkali monometal complex such as disodium monocopper(II) citrate dihydrate or disodium monozinc(II) citrate dihydrate and triethanolamine lauryl sulfate in a concentration of less ... 04/20/06 - 20060083693 - Stable pharmaceutical solution formulations for pressurised metered dose inhalers An aerosol solution composition for use in an aerosol inhaler comprises an active material, a propellant containing a hydrofluoroalkane, a cosolvent and optionally a low volatility component to increase the mass median aerodynamic diameter (MMAD) of the aerosol particles on actuation of the inhaler. The composition is stabilized by using ... 04/20/06 - 20060083692 - Combination of formoterol and a tiotropium salt A medicament containing, separately or together, (A) formoterol or a pharmaceutically acceptable salt thereof or a solvate of formoterol or said salt and (B) a tiotropium salt of a pharmaceutically acceptable acid, for simultaneous, sequential or separate administration in the treatment of an inflammatory or obstructive airways disease. ... 04/20/06 - 20060083691 - Intranasal opioid compositions, delivery devices and methods of using same The present invention relates to pharmaceutical compositions comprising opioids and a liquid nasal carrier, to delivery devices comprising such compositions, and to methods of manufacture and use of such compositions. ... 04/13/06 - 20060078506 - Methods, systems and devices for noninvasive pulmonary delivery The invention is directed to noninvasive methods, systems and devices for pulmonary delivery of aerosolized active agents and methods of treating respiratory dysfunction. ... 04/13/06 - 20060078505 - Methods and kits for delivering drugs by nebulisation Methods for administering drugs by nebulisation, together with kits for carrying out the methods, and including components for the production of such kits and unit dose vials. ... 04/13/06 - 20060078504 - Sustanined-release pharmaceutical composition for lung administration The present invention provides a sustained-release pharmaceutical composition containing a pharmacologically active substance, the pharmaceutical composition being able to control the pulmonary absorption of the pharmacologically active substance and produce prolonged pharmacological effects when administered via the pulmonary route. The invention provides a pharmaceutical composition containing carrageenan and a pharmacologically ... 04/06/06 - 20060073104 - Apoe4 domain interaction inhibitors and methods of use thereof The present invention provides compounds that inhibit apoE4 domain interaction; and compositions, including pharmaceutical compositions, comprising the compounds. The present invention provides methods of treating apoE4-related disorders. The methods generally involve administering to an individual in need thereof a therapeutically effective amount of an apoE4 domain interaction inhibitor. ... 04/06/06 - 20060073103 - Controlled dosage aerosols with lecithin as surface-active agent A controlled dosage aerosol containing at least one medicinal agent, pressure-liquefied isobutane as the propellant, and lecithin as the surfactant. ... 03/23/06 - 20060062739 - Inhalable lidocaine formulation for treatment of asthma and for reducing the need for corticosteroids in asthmatic patients An inhalable lidocaine solution for treatment of asthma and a method for treatment of asthma with the reduced need for concurrent administration of oral corticosteroids in asthmatic patients. The lidocaine solution or lidocaine dry powder is delivered by an electronic nebulizer or by dry powder inhaler or dose meter one ... 03/23/06 - 20060062738 - Method for improvement of tolerance for therapeutically effective agents delivered by inhalation A method for improvement of tolerance for therapeutically effective agents delivered by inhalation comprising a pretreatment of a patient with a nebulized lidocaine or a lidocaine-like compound administered immediately or up to about thirty minutes before administration of the primary therapeutically effective agent. The pretreatment of the patient with the ... 03/23/06 - 20060062737 - Targeted delivery of lidocaine and other local anesthetics and a method for treatment of cough and tussive attacks An anti-tussive nebulized solution for targeted delivery of lidocaine into conducting and central airways. A method for treatment of cough and tussive attacks or episodes using said lidocaine solution. A nebulized lidocaine solution administered in daily dose from about 10 mg to 80 mg of lidocaine dissolved in a saline ... 03/23/06 - 20060062736 - Therapeutic foam A therapeutic foam for the treatment of, inter alia, varicose veins comprises a sclerosing solution foamed with a physiological gas such as carbon dioxide, oxygen or a mixture thereof. The foam has a nitrogen content of less than 0.8%. It may be generated using a pressurised canister system incorporating a ... 03/23/06 - 20060062735 - Combination therapy and means for carrying out said therapy Disclosed is a combination therapy comprising permanent administration of a transdernal therapeutic system (TTS) in order to provide a patient with a basic supply of a pharmaceutical agent and initial administration of the same pharmaceutical agent by means of a spray, allowing the lag time observed in a TTS therapy ... 03/16/06 - 20060057073 - Wet granulation process The invention is in the field of pharmaceutical dosage forms, and more particularly in the field of pharmaceutical granules and processes for making granules. The invention provides a process for preparing pharmaceutical granules which contain an active ingredient in the form of a salt, said process comprising the steps of ... 03/02/06 - 20060045849 - Method of customizing the fragrance of nasal medications Disclosed is a process for improving the scent of nasal medication comprising the steps of presenting a person with a fragrance choice comprised of a plurality of fragrance selections, receiving from the person a selection of a fragrance from said fragrance choice, thereby producing a selected fragrance, and adding to ... 03/02/06 - 20060045848 - Conscience-enhancing malice-weakening gas This invention is a mixture of neuroactive substances in the form of gases, liquid aerosols, and/or solid aerosols, which act synergistically to increase the ratio of strength between the desire to do right, called conscience, and the desire to do wrong, called malice. Neurochemically, that corresponds to increasing the ratio ... 02/23/06 - 20060039868 - Inhalable powder containing tiotropium The invention relates to powdered preparations containing tiotropium for inhalation, processes for preparing them as well as their use in preparing a pharmaceutical composition for the treatment of respiratory complaints, particularly for the treatment of COPD (chronic obstructive pulmonary disease) and asthma. ... 02/23/06 - 20060039867 - Method for treating sleep-related breathing disorders with setiptiline Compositions and methods for the treatment of sleep related breathing disorders are provided. Compositions include setiptiline in combination with other active pharmaceutical ingredients, such as zonisamide, topiramate or modafinil. The treated sleep related breathing disorders include sleep apnea and sleep hypopnea. In some embodiments, the pharmaceutical compounds are used as ... 02/23/06 - 20060039866 - Method for treating sleep-related breathing disorders Compositions and methods for the treatment of sleep related breathing disorders are provided. Compositions include mirtazapine in combination with other active pharmaceutical ingredients, such as zonisamide, topiramate or modafinil. The treated sleep related breathing disorders include sleep apnea and sleep hypopnea. In some embodiments, the pharmaceutical compounds are used as ... 02/16/06 - 20060034776 - Inhalable medicaments containing a new anticholinergic, corticosteroids, and betamimetics wherein X− is an anion with a single negative charge; (b) at least one corticosteroid (2); and (c) at least one betamimetic (3), and the enantiomers, mixtures of the enantiomers, racemates, solvates, hydrates, or physiologically acceptable acid addition salts thereof, processes for preparing them and their use in the treatment ... 02/16/06 - 20060034775 - Aerosol formulation for inhalation containing an anticholinergic wherein: X− is chloride, bromide, iodide, sulfate, phosphate, methanesulfonate, nitrate, maleate, acetate, citrate, fumarate, tartrate, oxalate, succinate, benzoate, or p-toluenesulfonate; and (b) at least one pharmacologically acceptable acid. ... 02/02/06 - 20060024239 - Persistent post-viral cough drug and treatment method A drug for treating persistent cough occurring after an acute viral upper respiratory infection that has a corticosteroid aerosol for inhalation, and labeling to indicate short-term use of the agent for persistent post-viral cough. Also a method for treating persistent post-viral cough that utilizes such a drug. ... 02/02/06 - 20060024238 - Compositions and methods using proton pump inhibitors The invention provides methods for treating and preventing gastrointestinal disorders, viral infections, fungal infections, Whipple's disease, sleep disorders, sleep apnea, iron deficiency anemia, asthma, nasal airway resistance, cystic fibrosis, pancreatitis, chemotherapy-induced emesis, radiation-induced injury to the gastrointestinal tract, epilepsy, middle ear infections, obesity, hiatal hernia, anorexia, bulimia, dental decay, post-operative ... 02/02/06 - 20060024237 - Dri nasal sprays There are provided safe, tasteless, odorless, non-aqueous liquid spray compositions formulated for administration to the nasal cavity consisting essentially of pharmacologically acceptable non aqueous liquid carrier in which said bioactive material is directly insoluble, a pharmacologically acceptable water insoluble ester of a water soluble acid soluble in said carrier, a ... 01/26/06 - 20060018840 - Aerosolizable formulation comprising nicotine An aerosolizable formulation comprises free-base nicotine, an organic acid, and a hydrofluoroalkane propellant. The organic acid is present in a mole ratio with said nicotine in a range of about 0.25:1 (organic acid:nicotine) to about 4:1 (organic acid:nicotine). The organic acid and said free-base nicotine form a nicotine salt. An ... 01/26/06 - 20060018839 - Methods and compositions using cholinesterase inhibitors The invention provides methods for treating and/or preventing Alzheimer's disease, psychiatric illnesses, encephalitis, meningitis, fetal alcohol syndrome, Karsakoff's syndrome, anoxic brain injury, cardiopulmonary resuscitation injuries, diabetes, Sjogren's syndrome, mental retardation, developmental delay, menopause, strokes, macular degeneration, neuronal loss associated with macular degeneration, sleep disorders, severe Alzheimer's disease, jet lag, post-traumatic ... 01/19/06 - 20060013777 - Novel treatment for cough The invention discloses the existence of cannabinoid receptors in the airways, which are functionally linked to inhibition of cough. Locally acting cannabinoid agents can be administered to the airways of a subject to ameliorate cough, without causing the psychoactive effects characteristic of systemically administered cannabinoids. In addition, locally or systemically ... 01/19/06 - 20060013776 - Methods and compositions for treating benign gynecological disorders An improvement in a method of treating benign gynecological disorders is described. In the method, treatment of a benign gynecological disorder with a composition comprised of a gonadotropin releasing hormone (GnRH) compound and an estrogenic compound, and optionally, an androgenic compound, is extended to premenopausal women who are not receiving ... 01/19/06 - 20060013775 - Use of ppar activators for the treatment of pulmonary fibrosis An activator of PPAR gamma is useful for the treatment of pulmonary fibrosis. ... 01/12/06 - 20060008420 - Nasal spray formulation and method A nasal spray formulation for use in female contraception or in the treatment of benign gynecological disorders is described. The nasal preparation is comprised of a GnRH compound and an estrogenic compound in the form of a water-soluble complex with a water-soluble cyclodextrin. The preparation effectively suppresses ovarian estrogen and ... 01/12/06 - 20060008419 - Biomedical foams The invention relates, generally, to porous absorbent materials which are suitable for packing antrums or other cavities of the human or animal body. More particularly, it relates to hydrophilic biodegradable foams, which may be used, e.g., in the form of a plug or tampon, for instance for controlling bleeding, wound ... 12/22/05 - 20050281753 - Buccal, polar and non-polar spray or capsule Buccal aerosol sprays or capsule using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprises formulation I: aqueous polar solvent 30-99.89%, active compound 0.001-60%, optionally ... 12/22/05 - 20050281752 - Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, active compound, and optional flavoring ... 12/22/05 - 20050281751 - Directed intranasal administration of pharmaceutical agents The invention includes methods, kits, compositions, and apparatus for intranasal administration of a compound such as a pharmaceutically active agent in a targeted manner. Such compounds can be delivered preferentially to a component of the central nervous system (CNS) such as the brain, the spinal cord, or cerebrospinal fluid. Such ... 12/22/05 - 20050281750 - Sprayable compositions comprising a combination of pharmaceutical active agents, an alcohol phase, at least one volatile silicone and a non-volatile oily phase Sprayable, anhydrous and physically/chemically stable dermatological/pharmaceutical compositions, well suited for the treatment of a variety of dermatological disorders, notably psoriasis, contain: a) a therapeutically effective amount of a solubilized corticord; notably clobetasol propionate; b) a therapeutically effective amount of a solubilized vitamin D derivative, notably calcitriol; c) an alcohol phase; ... 12/22/05 - 20050281749 - Sprayable compositions comprising a combination of pharmaceutical actives and an oily phase Sprayable, anhydrous and physically/chemically stable dermatological/pharmaceutical compositions, well suited for the treatment of a variety of dermatological disorders, notably psoriasis, contain: a) a therapeutically effective amount of a solubilized corticoid, notably dissolved clobetasol propionate; b) a therapeutically effective amount of a solubilized vitamin D derivative, notably dissolved calcitriol; and c) ... 12/08/05 - 20050271596 - Vasoactive kit and composition and uses thereof The present invention relates to a therapeutic kit to provide a safe and effective dosage of a vasoactive agent, including an aerosol packaging assembly including: a container accommodating a pressurized product; and an outlet capable of releasing the pressurized product as a foam, wherein the pressurized product comprises a foamable ... 11/24/05 - 20050260138 - Producton and use of a gaseous vapor disinfectant Smoke or vapor generating system disperses an airborne biocidal oil, such as methyl soyate, to decontaminate and area or object. The airborne forms of methyl soyate are have broad spectrum efficacy against a wide variety of microscopic pathogens including viruses, bacteria and fungi. ... 11/03/05 - 20050244339 - Pharmaceutical aerosol composition Sterile compositions for administration as aerosols are described. They contain an active agent which is poorly water-soluble, a non-ionic surfactant acomponent and a phospholipid component. The compositions are suitable for oral or nasal inhalation, but also for topical or oromucosal administration. They are particulary useful for the efficient pulmonary administration ... 10/20/05 - 20050232872 - Compositions and methods for enhancing receptor-mediated cellular internalization Compositions and methods for improving cellular internalization of one or more compounds are disclosed. The compositions include a compound to be delivered and a biocompatible viscous material, such as a hydrogel, lipogel, or highly viscous sol. The composition also include, or are administered in conjunction with, an enhancer in an ... 10/20/05 - 20050232871 - Use of compounds in a dry powder inhaler The present invention relates to an inhaled formulation comprising a compound selected from a particular class of 5,6-dihydro-9H-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridines which is capable of delivering the compound as fine, solid particles to the lung and the use of such a formulation in the treatment of certain diseases such as respiratory diseases. By ... 10/20/05 - 20050232870 - Method of treatment of dopamine-related dysfunction The present invention relates to the treatment of dopamine-related dysfunction using full D1 dopamine receptor agonists in an intermittent dosing protocol with a short, but essential, “off-period.” The D1 agonist concentration is reduced during the “off-period” to obtain a plasma concentration of agonist that suboptimally activates D1 dopamine receptors for ... 10/20/05 - 20050232869 - Nonsteroidal immunomodulating kit and composition and uses thereof A composition and therapeutic kit including an aerosol packaging assembly including a container accommodating a pressurized product and an outlet capable of releasing a foamable composition, including a nonsteroidal immunomodulating agent as a foam. The pressurized product includes a foamable composition including: a) a container accommodating a pressurized product; and ... 10/20/05 - 20050232868 - Methods of entrapping, inactivating, and removing viral infections by the administration of respiratory tract compositions The present invention is directed to methods of preventing and treating respiratory tract viral infections by administering compositions to areas of the respiratory tract such as the nasal cavity, wherein the compositions provide for the encapsulation, inactivation, and/or removal of viruses and/or viral strains associated with the common cold and ... 10/20/05 - 20050232867 - Pharmaceutical compositions and methods for peptide treatment Compositions and methods for treating a patient with a pharmaceutically active peptide that combines a pharmaceutically active peptide, a permeation enhancer, and a carrier, are disclosed. ... 10/06/05 - 20050220719 - Nasal passage cleaning composition A nasal passage cleaning composition comprises a saline base and contains non-steroidal natural ingredients at a buffeted comfortable pH. The composition cleans and clears the nasal passages and relieves pain, with limited irritation and substantially no side effects. ... 10/06/05 - 20050220718 - Stable pharmaceutical solution formulations for pressurized metered dose inhalers Aerosol solution formulations for use in an aerosol inhaler which comprise 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]-ethyl]-2(1H)-quinolinone or a salt thereof, in particular the hydrochloride salt (TA 2005), as an active ingredient, a propellant containing a hydrofluoroalkane, and a cosolvent, stabilized by addition of a specific small amount of a high concentrated phosphoric acid exhibit ... 10/06/05 - 20050220717 - Steroid solution aerosol products with enhanced chemical stability A medicinal aerosol steroid solution formulation product with enhanced chemical stability. The steroid is a 20-ketosteroid having an OH group at the C-17 or C-21 position and the aerosol container has a non-metal interior surface which has been found to reduce chemical degradation of such steroids. ... 10/06/05 - 20050220716 - Drug delivery assembly This invention relates to a drug delivery assembly which includes a pressurised container (10) holding a drug formulation with a propellant, the container being disposed within a sealed enclosure (12) forming an overwrap or secondary packaging comprising a gas adsorbing material consisting of a microporous zeolite having a pore opening ... 09/29/05 - 20050214225 - Pharmaceutical composition and nasal rinsing device therefor The aromatic composition is for nasal administration and has a pharmaceutically-acceptable aqueous saline solution carrier combined with sesame oil and an essential oil such as peppermint oil and eucalyptus oil. The composition is withdrawn into a syringe and an output portion is sealingly applied to the nostril before the composition ... 09/29/05 - 20050214224 - Lipid formulations for spontaneous drug encapsulation A pharmaceutical formulation for pulmonary administration is disclosed. The pharmaceutical formulation comprises a lipid component and an active agent, wherein the pharmaceutical formulation has a liquid phase transition temperature of less than or equal to 37° C. when hydrated and a liquid phase transition temperature of greater than 57° C. ... 09/22/05 - 20050207987 - Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics A patient suffering from an endobronchial infection is treated by administering to the patient for inhalation a dose of less than about 4.0 ml of a nebulized aerosol formulation comprising from about 60 to about 200 mg/ml of an aminoglycoside antibiotic, such as tobramycin, in a physiologically acceptable carrier in ... 09/22/05 - 20050207986 - Stabilized preparations for use in nebulizers Stabilized dispersions are provided for the delivery of a bioactive agent to the respiratory tract of a patient. The dispersions preferably comprise a stabilized colloidal system which may comprise a fluorochemical component. In particularly preferred embodiments, the stabilized dispersions comprise perforated microstructures dispersed in a fluorochemical suspension medium. As density ... 09/22/05 - 20050207985 - Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease The present invention relates to a dual bronchodilator inhalation solution, system, kit and method for relieving bronchospasm in patients suffering from chronic obstructive pulmonary disease (COPD). In one alternative embodiment, the solution of the present invention is a prepackaged, sterile, premixed, premeasured single unit dose of albuterol and ipratropium bromide ... 09/22/05 - 20050207984 - Formoterol and ciclesonide aerosol formulations A pharmaceutical aerosol formulation comprising particles of formoterol or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, said particles being suspended in the formulation; a compound of the formula (I), in which: R1 is 1-butyl, 2-butyl, cyclohexyl or phenyl and R2 is acetyl or isobutanoyl, said compound of ... 09/15/05 - 20050201947 - Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics A patient suffering from an endobronchial infection is treated by administering to the patient for inhalation a dose of less than about 4.0 ml of a nebulized aerosol formulation comprising from about 60 to about 200 mg/ml of an aminoglycoside antibiotic, such as tobramycin, in a physiologically acceptable carrier in ... 09/15/05 - 20050201946 - Intranasal influenza virus vaccine Aminopiperidine derivatives and pharmaceutically acceptable derivatives thereof are disclosed. Such derivatives are useful in methods of treatment of bacterial infections in mammals, particularly in man. ... 09/15/05 - 20050201945 - Medicament dispenser A dispenser for dispensing a medicament that includes a canister for housing the medicament and a fluid propellant therefor and a drug-dispensing valve wherein one or more of the internal surfaces of the canister and/or valve includes a fluorinated coating prepared from plasma polymerisation of one or more fluorinated monomers ... 09/08/05 - 20050196345 - Compressed air inhaler for pulmonary application of liposomal powder aerosols and powder aerosols The aim of the invention, providing an inhaler with which the pulmonary application of, in particular, liposomes carrying active agent is enabled without forced breathing manoeuvres and with which the active agent can be transferred to the desired place of action in a sufficient amount without the active agent escaping, ... 09/08/05 - 20050196344 - Methods and devices for blocking flow through collateral pathways in the lung Disclosed is a method of regulating fluid flow for a targeted lung region. The method comprises injecting a therapeutic agent into the targeted lung region. The therapeutic agent induces a reaction in lung tissue of the targeted lung region or in a collateral pathway to the lung region to reduce ... 09/01/05 - 20050191245 - Nasal administration of calcium channel, blockers for treatment of hypertension and other cardiovascular disorders Pharmaceutical compositions useful for the treatment of cardiovascular disorders such as hypertension are described. These compositions are formulated for nasal administration and comprise a therapeutically effective amount of a calcium channel blocker, optionally a pharmaceutically acceptable carrier that is suitable for nasal administration, and one or more optional members selected ... 08/25/05 - 20050186142 - Kit and composition of imidazole with enhanced bioavailability A composition and therapeutic kit provide a therapeutic azole with increased solubility. The kit includes an aerosol packaging assembly containing a container accommodating a pressurized product and an outlet capable of releasing the pressurized product as a foam. The pressurized product includes a foamable composition including: i. a therapeutic azole, ... 08/25/05 - 20050186141 - Transdermal aerosol compositions The present invention provides a pharmaceutical composition for transdermal delivery comprising: one or more physiologically active agents; one or more dermal penetration enhancers; a pharmaceutically acceptable carrier comprising a volatile solvent; and a hydrofluorocarbon propellent; wherein the carrier and penetration enhancers combine to provide a single-phase solution of the one ... 08/18/05 - 20050180924 - Composition and method for moisturizing nasal tissue An improved composition and method for moisturizing a nasal membrane are disclosed. The composition includes a viscous carrier and one or more moisturizing agents disposed with the carrier. The composition is applied to a portion of a nasal membrane using a spray, a swab applicator, or a similar application device. ... 08/18/05 - 20050180923 - Buccal, polar and non-polar spray containing testosterone Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide testosterone for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, testosterone or a pharmaceutically acceptable ester thereof, ... 08/11/05 - 20050175544 - Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma The present invention relates to an albuterol inhalation solution, system, kit and method for relieving bronchospasm in children suffering from asthma. In one alternative embodiment, the solution of the present invention is a sterile, premixed, premeasured single unit dose of albuterol for asthmatic patients 2 to 12 years of age. ... 07/28/05 - 20050163722 - Optimised formulation of tobramycin for aerosolization The invention provides a tobramycin formulation for delivery by aerosolization in the form of additive-free, isotonic solution whose pH has been optimised to ensure adequate shelf-life at room temperature. Said formulation can be advantageously used for the treatment and prophylaxis of acute and chronic endobronchial infections, in particular those caused ... 07/28/05 - 20050163721 - Container for the generation of therapeutic microfoam The device containing sclerosant liquid for use in the treatment of blood vessles comprises an aerosol valve housing mounted on a canister having an expandable inner container in which the sclerosant fluid is contained, wherein the expandable inner container is affixed to the outer opening of the canister or to ... 07/28/05 - 20050163720 - Carboxylic acid compounds for use as surfactants R1 and R2 independently represent —C1-9 alkyleneC1-6 fluoroalkyl, which fluoroalkyl moiety contains at least 1 fluorine atom and not more than 3 consecutive perfluorocarbon atoms and wherein the R1 and/or R2 moiety is optionally interrupted by an ether link, processes for their preparation, use of the compounds in the preparation ... 07/21/05 - 20050158247 - Nasal peptide pharmaceutical formulation (2) a therapeutically effective amount of active nasal peptide, its pharmaceutically acceptable salt or its peptidic fragment; in a pharmaceutically acceptable, aqueous liquid diluent or carrier, said formulation being in a form suitable for nasal administration. ... 07/14/05 - 20050152844 - Transpulmonary systemic cooling using liquid mists A method for transpulmonary cooling by providing a liquid having a boiling point of 38-300° C., more preferably 38-250° C., more preferably 38-200° C., more preferably 38-150° C., more preferably 38-80° C. The liquid is nebulized to form a mist. The mist is optionally cooled below room temperature and delivered ... 07/07/05 - 20050147565 - Pharmaceutical compositions for the treatment of asthma Disclosed are aerosolized formulations for the treatment of asthma that contain mometasone furoate and formoterol fumarate and processes for preparing the same. ... 06/30/05 - 20050142071 - Pressurised metered dose inhalers (mdi) The invention relates to the use of pressurised metered dose inhalers (MDIs) having part or all of their internal surfaces consisting of stainless steel, anodised aluminium or lined with an inert organic coating; and to compositions to be delivered with said MDIs. ... 06/30/05 - 20050142070 - Methods and systems for assessing pulmonary disease with drug therapy control An external respiratory therapy device incorporates sensors that may be used to sense physiological conditions or parameters associated with pulmonary disease. The sensed conditions may be used to detect and/or to assess a presence of various types of pulmonary diseases. The assessment of the pulmonary disease may be utilized to ... 06/30/05 - 20050142069 - Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, active compound, and optional flavoring ... 06/16/05 - 20050129622 - Nasal composition comprising a mucopolysaccharide and propylene glycol The invention relates to pharmaceutical compositions adapted to nasal administration. The nasal formulations of the invention are characterized inter alia by having excellent moisturizing properties and not requiring a preservative. ... 06/16/05 - 20050129621 - Aerosol formulations for pulmonary administration of medicaments to produce a systemic effect The invention discloses an aerosol pharmaceutical composition comprising a medicament in solution in a mixture of a hydrfluoroalkane propellant and one or more co-solvents wherein the aerosol liquid droplets delivered on actuation of the inhaler have a particle size comprised between 0.5 μm and 2.5 μm, with a mass median ... 06/16/05 - 20050129620 - Metering valve and pharmaceutical metered dose inhaler and methods thereof Methods of treating an elastomeric substrate that include, in any suitable order, providing an elastomeric substrate in a bath including an alcohol and an alkaline material at a bath temperature effective for treatment, providing ultrasonic energy at a treatment-effective frequency and power level to the bath for a time period ... 06/09/05 - 20050123484 - Non-flammable topical anesthetic liquid aerosols A topical liquid aerosol formulation for accurate metered dose delivery has been developed which includes a concentrate comprising a local anesthetic in a non-alcohol solvent and a hydrofluorocarbon (HFC) propellant. In the preferred embodiment, the concentration of the non-alcohol solvent in the concentrate is between about 75% and 85% by ... 06/09/05 - 20050123483 - Portable gas operating inhaler The invention relates to an inhaler comprising a compressed gas, such as Heliox gas in a first chamber which is in communication with an equalization chamber having pressure lower than the pressure of the gas in the first compressed chamber and having a drug storage chamber which is detachably coupled ... 06/02/05 - 20050118110 - Apparatus and method for stabilizing concentration of aerosol Provided is an apparatus for stabilizing the concentration of a previously generated aerosol, which includes: an aerosol inlet channel; an aerosol pressure adjustment unit accelerating the aerosol; a buffer connected to the aerosol pressure adjustment unit via an aerosol transport channel and having a much larger sectional area than the ... 06/02/05 - 20050118109 - Method for treating lung diseases associated with ventilation-perfusion mismatches The present invention relates to pharmaceutical compositions and methods for the prevention and/or treatment of lung diseases or disorders including the bronchial tree, in an animal or human, such as chronic obstructive pulmonary disease (COPD), and diseases related to or optionally associated with COPD-like lung disorders caused by ventilation-perfusion mismatches ... 06/02/05 - 20050118108 - Pulmonary delivery of a liquid medicament aerosol The invention is directed to liquid compositions containing a drug and liquid carrier vehicles for direct pulmonary delivery of a pharmaceutically active agent to a patient in need of treatment wherein the liquid carrier vehicle consists primarily of a fluorocarbon liquid and a co-solvent such as ethanol and to methods ... 06/02/05 - 20050118107 - Composition for inhalation The invention relats to a novel pharmaceutical composition useful in the treatment of respiratory disorders such as asthma, rhinitis and chronic obstructive pulmonary disease (COPD). The composition comprises formoterol. ... 06/02/05 - 20050118106 - Aqueous foaming composition The invention provides an aqueous foaming composition, an expanded foam composition and a process of forming a foam composition concentrate. The aqueous foaming composition comprises a carbonised saccharide mixture, a surfactant, water and optionally further agents including thickeners, solvents, stabilisers, buffers, corrosion inhibitors and preservatives. Foaming compositions of the present ... ### FreshPatents.com Support |